BCRX
Price:
$7.6
Market Cap:
$1.57B
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, w...[Read more]
Industry
Biotechnology
IPO Date
1994-03-04
Stock Exchange
NASDAQ
Ticker
BCRX
According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.78. This represents a change of -11.93% compared to the average of 3.16 of the last 4 quarters.
The mean historical Current Ratio of BioCryst Pharmaceuticals, Inc. over the last ten years is 2.56. The current 2.78 Current Ratio has changed 10.75% with respect to the historical average. Over the past ten years (40 quarters), BCRX's Current Ratio was at its highest in in the March 2022 quarter at 6.32. The Current Ratio was at its lowest in in the March 2016 quarter at 0.80.
Average
2.56
Median
1.73
Minimum
1.02
Maximum
5.46
Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 78.10%
Maximum Annual Current Ratio = 5.46
Minimum Annual Increase = -43.90%
Minimum Annual Current Ratio = 1.02
Year | Current Ratio | Change |
---|---|---|
2023 | 3.31 | -32.45% |
2022 | 4.90 | -10.32% |
2021 | 5.46 | 78.10% |
2020 | 3.06 | 72.19% |
2019 | 1.78 | 8.14% |
2018 | 1.65 | -1.77% |
2017 | 1.68 | 35.97% |
2016 | 1.23 | 20.36% |
2015 | 1.02 | -33.89% |
2014 | 1.55 | -43.90% |
The current Current Ratio of BioCryst Pharmaceuticals, Inc. (BCRX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
4.55
5-year avg
3.70
10-year avg
2.56
BioCryst Pharmaceuticals, Inc.’s Current Ratio is less than TG Therapeutics, Inc. (4.59), greater than Axsome Therapeutics, Inc. (2.44), less than Intercept Pharmaceuticals, Inc. (4.22), greater than Seres Therapeutics, Inc. (1.12), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Kezar Life Sciences, Inc. (7.65), greater than Immunic, Inc. (2.71), greater than Atara Biotherapeutics, Inc. (0.59), less than Pieris Pharmaceuticals, Inc. (4.82), less than Apellis Pharmaceuticals, Inc. (4.36), less than Blueprint Medicines Corporation (3.32), less than Karuna Therapeutics, Inc. (19.31), less than Mirati Therapeutics, Inc. (7.54), less than Day One Biopharmaceuticals, Inc. (14.62), less than Anavex Life Sciences Corp. (12.04), less than Cassava Sciences, Inc. (3.55), greater than INmune Bio, Inc. (2.59), less than BioVie Inc. (2.95), greater than Cognition Therapeutics, Inc. (2.11), less than Viking Therapeutics, Inc. (36.47), less than X4 Pharmaceuticals, Inc. (4.89), greater than PDS Biotechnology Corporation (0.00),
Company | Current Ratio | Market cap |
---|---|---|
4.59 | $5.46B | |
2.44 | $4.78B | |
4.22 | $794.69M | |
1.12 | $131.23M | |
5.98 | $7.58B | |
7.65 | $54.72M | |
2.71 | $99.09M | |
0.59 | $66.06M | |
4.82 | $22.15M | |
4.36 | $3.83B | |
3.32 | $5.98B | |
19.31 | $12.60B | |
7.54 | $4.12B | |
14.62 | $1.38B | |
12.04 | $772.49M | |
3.55 | $1.27B | |
2.59 | $107.98M | |
2.95 | $54.19M | |
2.11 | $17.77M | |
36.47 | $5.86B | |
4.89 | $57.64M | |
0.00 | $78.19M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is BioCryst Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the highest Current Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 3-year average Current Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 5-year average Current Ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?
How does the current Current Ratio for BioCryst Pharmaceuticals, Inc. (BCRX) compare to its historical average?